Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APAS
- PDF / 1,011,764 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 107 Downloads / 173 Views
ORIGINAL ARTICLE
Pre‑existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID‑19 Liver Injury Spectrum Study) Shiv Kumar Sarin1 · Ashok Choudhury1 · George K. Lau2 · Ming‑Hua Zheng2,3 · Dong Ji2,4 · Sherief Abd‑Elsalam5 · Jaeseok Hwang6 · Xiaolong Qi7 · Ian Homer Cua8 · Jeong Ill Suh9 · Jun Gi Park9 · Opass Putcharoen10 · Apichat Kaewdech11 · Teerha Piratvisuth11 · Sombat Treeprasertsuk10 · Sooyoung Park12 · Salisa Wejnaruemarn10 · Diana A. Payawal13 · Oidov Baatarkhuu14 · Sang Hoon Ahn15 · Chang Dong Yeo15 · Uzziel Romar Alonzo13 · Tserendorj Chinbayar16 · Imelda M. Loho17 · Osamu Yokosuka18 · Wasim Jafri19 · Soeksiam Tan20 · Lau Ing Soo20 · Tawesak Tanwandee21 · Rino Gani22 · Lovkesh Anand23 · Eslam Saber Esmail5 · Mai Khalaf5 · Shahinul Alam24 · Chun‑Yu Lin25 · Wan‑Long Chuang25 · A. S. Soin26 · Hitendra K. Garg27 · Kemal Kalista28 · Badamnachin Batsukh14 · Hery Djagat Purnomo29 · Vijay Pal Dara30 · Pravin Rathi31 · Mamun Al Mahtab24 · Akash Shukla32 · Manoj K. Sharma1 · Masao Omata33,34 · APASL COVID Task Force, APASL COVID Liver Injury Spectrum Study (APCOLIS Study-NCT 04345640) Received: 12 June 2020 / Accepted: 27 June 2020 © Asian Pacific Association for the Study of the Liver 2020
Abstract Background and aims COVID-19 is a dominant pulmonary disease, with multisystem involvement, depending upon comorbidities. Its profile in patients with pre-existing chronic liver disease (CLD) is largely unknown. We studied the liver injury patterns of SARS-Cov-2 in CLD patients, with or without cirrhosis. Methods Data was collected from 13 Asian countries on patients with CLD, known or newly diagnosed, with confirmed COVID-19. Results Altogether, 228 patients [185 CLD without cirrhosis and 43 with cirrhosis] were enrolled, with comorbidities in nearly 80%. Metabolism associated fatty liver disease (113, 61%) and viral etiology (26, 60%) were common. In CLD without cirrhosis, diabetes [57.7% vs 39.7%, OR = 2.1 (1.1–3.7), p = 0.01] and in cirrhotics, obesity, [64.3% vs. 17.2%, OR = 8.1 (1.9–38.8), p = 0.002] predisposed more to liver injury than those without these. Forty three percent of CLD without cirrhosis presented as acute liver injury and 20% cirrhotics presented with either acute-on-chronic liver failure [5 (11.6%)] or acute decompensation [4 (9%)]. Liver related complications increased (p
Data Loading...
